Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What are the potential numbers bird?
Silence Therapeutics PLC 27 July 2017 Licensee Quark Pharmaceuticals announces positive Phase 2 data in Acute Kidney Injury 27 July 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, notes Quark Pharmaceutical, Inc's ("Quark") press release "Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery". Quark reported that the trial's primary endpoint and multiple secondary endpoints were met. Quark holds a licence to Silence's chemical modification technology. Silence is eligible to receive either approximately 2% royalties from Quark (on QPI-1002) plus milestones, or 15% of the clinical, regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis. Quark's full announcement can be found here: http://quarkpharma.com/?p=12442.
IMHO I think this share is a little belter. I recall the £4 days and I have been troubled by this low ebb for so long but I have stuck with it. The patent in USA gives me real excitement and fingers crossed for a big few months ahead. GLA.
Well it must be after 3rd July (SLN RNS) and has a date of 11th July which I assume is the publish date. I noticed that hordes of AT automated trades pushed the price up, anyone more knowledgeable than I here who can help me understand the significance of this (if any)? Thanks in advance
Hi, Is this a new note ? Thanks
Look at volume...step change... Massive upside...
Is that a new note ? TYIA
fairly convincing
Sell high....
Silence is golden...
And Alnylam's market cap is $7.5 billion.....
Some buys... Buy low...
Pops up.... read the most recent RNS ..... great buying time now.... don't be late to the party .... buy right and you don't have to worry .... another EMH and PRSM in my mind ....
Massive upside...
Apologies. Wrong board.
Only just noticed the latest rns. Excellent news. I hope it does the trick and gets us somewhere close to the 20p.
Although today's rise looks like a reversal, I can't see it as a confirmed reversal. Maybe it will attract more speculative buyers in the next few days?
Cmon 8am Nice fill at 90p or thereabouts. The usual 20%+ from Align will pay for the next ski trip Allez Align Merci
I see Align Research's next winner is Silence Therapeutics I've recently followed Align into DryShips,GRIT,ITM,Providence and Zenith.....haven't had a loser I note last year SLN moved from 100 to 130p Expect news shortly on drug update and final figs Long time dormant but I'm here there on the open to snaffle a few Thanks Align for an early Easter present!
a year later, cash is way down..and why not sub 50p now?
Zzzzzzzzzzzzz
increasing volumes? is an acquisition in sight?
?
Anybody knows why the shares are up 14.49% ?
only see one trade on the ISDX. There have been some trades in excess of �10,000 over the last five days on AIM. Maybe somebody trying to snag a few shares prior to a positive update, though volumes are low. Maybe summer holidays over and some interest starting??